Difference between revisions of "Cladribine (Leustatin)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m |
|||
| Line 22: | Line 22: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * 2/26/1993: Initial FDA approval | + | * 2/26/1993: Initial FDA approval for treatment of active [[hairy cell leukemia]] |
==Also known as== | ==Also known as== | ||
Revision as of 00:55, 23 September 2020
General information
Class/mechanism: Purine analog; mimics the nucleoside adenosine, inhibiting adenosine deaminase, which interferes with DNA synthesis and repair.[1][2]
Route: IV, SC
Extravasation: irritant or neutral, depending on reference
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Acute myeloid leukemia
- Chronic lymphocytic leukemia
- Hairy cell leukemia
- Hypereosinophilic syndrome
- Langerhans cell histiocytosis
- Mantle cell lymphoma
- Marginal zone lymphoma
- Systemic mastocytosis
- Waldenström macroglobulinemia
Patient drug information
- Cladribine (Leustatin) patient drug information (Chemocare)[3]
- Cladribine (Leustatin) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 2/26/1993: Initial FDA approval for treatment of active hairy cell leukemia
Also known as
- Generic names: 2-chlorodeoxyadenosine, 2-CdA
- Brand names: Leustatin, Litak, Movectro
References
Categories:
- Drugs
- Intravenous medications
- Subcutaneous medications
- Irritant
- Neutral
- Antimetabolites
- Purine analogues
- Acute myeloid leukemia medications
- Chronic lymphocytic leukemia medications
- Hairy cell leukemia medications
- Hypereosinophilic syndrome medications
- Langerhans cell histiocytosis medications
- Mantle cell lymphoma medications
- Marginal zone lymphoma medications
- Systemic mastocytosis medications
- Waldenström macroglobulinemia medications
- FDA approved in 1993